Few treatment options exist for exposure to high doses of ionizing radiation over a short period of time, which would be expected following the meltdown of a nuclear reactor and other scenarios.
Stem Cell Competition Heating Up
August 23, 2010 By 2 Comments
According to the National Institutes of Health’s [NIH] stem cell primer, stem cells have the ability to develop into many different cell types in the body during early life and growth. In many tissues they serve as an internal repair system, dividing essentially without limit to replenish other cells. When a stem cell divides, each [...]
Gut Check Time for GVHD Companies: BMT Tandem Meetings Review
February 28, 2010 By 2 Comments
The 2010 BMT Tandem Meetings were held in Orlando, Florida this past week [February 24-28, 2010]. Considered the premier event for hematopoietic cell transplantation [HCT] and cellular therapy, the annual event attracts more than 2,500 clinicians, transplant nurses, clinical research professionals, data managers, pharmacists, center administrators and mid-level practitioners. With more than 200 abstracts being [...]
2009: Biotech’s Stealth Small Cap Rally
January 3, 2010 By 2 Comments
On the heels of the Dow Jones Industrial Average (DJIA) logging its worst annual performance since 1931 and the NASDAQ Composite (COMP) having its worst year since inception in 1971, it may have seemed counter intuitive to provide a bullish outlook for the biotechnology industry in 2009. Nonetheless, at the start of the year we [...]
Graft Versus Host Disease: Failures and Future Opportunities
December 9, 2009 By 7 Comments
In September 2009, Osiris Therapeutics, Inc. (OSIR) reported preliminary results from two Phase III trials evaluating its Prochymal product candidate for the treatment of acute Graft-versus-Host disease [GVHD]. Unfortunately, neither trial reached its primary endpoint, sending shares from $14 to a 52-week low of $5.35 by November 2009. The results were the latest in a [...]
Follow MD Becker Partners